BioIVT, a leading provider of biospecimens, research models and drug and diagnostic development services, acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypex's extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism.
"We are delighted that the Cypex team is joining BioIVT, bringing with them not only their market-leading products, but also their in vitro drug metabolism technology expertise," said BioIVT Chief Executive Officer Richard Haigh. "The acquisition of Cypex enhances BioIVT's product portfolio, ensuring that we continue to meet all our biopharmaceutical customers' research requirements for their entire R&D pipeline."
"This is a good match. We view BioIVT as a like-minded partner; we share the same commitment to supplying high quality products and passion for ensuring that our customers have the best products for their research," said Dr. Michael Voice, Co-lead Scientist at Cypex. "We are excited that our customers will gain access to BioIVT's hepatocytes and other hepatic products, and benefit from its well-established global biospecimen network, and robust supply chain."
BioIVT will continue to operate from the ISO 9001 certified manufacturing facility in Dundee. Financial details about this transaction were not disclosed.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!